Nimotuzumab with Lonsurf for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding nimotuzumab (a targeted antibody) to Lonsurf (a chemotherapy pill) can help people with metastatic colorectal cancer that has not responded to at least two prior treatments. It is for patients whose tumors have specific genetic markers (RAS and BRAF wild-type, MSS/pMMR) and who have previously benefited from an EGFR-blocking drug like Erbitux or Vectibix.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread to other parts of the body (metastatic) and has gotten worse after at least two prior standard treatments.
- Your last treatment with an EGFR-blocking drug (like Erbitux or Vectibix) either shrunk your tumor or kept it stable, and it has been more than 4 months since you stopped that drug.
- Your tumor has no mutations in the RAS or BRAF genes, and it is MSS (stable microsatellite status) or pMMR (normal mismatch repair).
- You are in good physical condition (ECOG score 0 or 1) and have adequate organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.